TScan Therapeutics, Inc.TCRXNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank17
3Y CAGR-42.4%
5Y CAGR-44.3%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-42.4%/yr
Annual compound
5Y CAGR
-44.3%/yr
Consistent
Percentile
P17
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
2 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 6.33% |
| 2024 | 21.78% |
| 2023 | 47.37% |
| 2022 | 33.07% |
| 2021 | 118.47% |
| 2020 | 117.93% |
| 2019 | 0.00% |